ARTICLE | Company News
Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China
January 18, 2019 12:52 AM UTC
Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China.
Ascletis believes KN035 is a potential first-in-class therapy for HBV. The company told BioCentury it expects to begin Phase II testing of the product for HBV in 2019...